StockNews.AI
ALGS
StockNews.AI
105 days

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

1. Aligos raised over $100M for Phase 2 study of ALG-000184. 2. Interim data show ALG-000184 has potential as standard HBV treatment. 3. ALG-055009 demonstrated significant liver fat reduction in recent trials. 4. Cash and investments totaled $137.9M, sufficient through 2026. 5. Aligos expects continued success in partnering discussions for ALG-055009.

Earnings
-13.27%Current Return
VS
-0.59%S&P 500
$5.0505/06 08:07 AM EDTEvent Start
$4.3805/07 03:04 PM EDTLatest Updated
15m saved
Insight
Article

FAQ

Why Bullish?

Successful fundraising and positive trial results signal strong potential for stock appreciation, similar to past biotech success stories like Gilead Sciences post-HBV treatment breakthroughs.

How important is it?

The article covers vital corporate developments and financial stability, critical for investor confidence.

Why Long Term?

Phase 2 data could significantly impact future market positioning. Historical patterns show companies often gain substantial market value following successful early-stage trials.

Related Companies

GILDVRTXABBV
May 06, 2025 08:00 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025. “We continued to make progress towards our corporate development plans aimed at advancing life-saving therapies for viral and liver diseases,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “Over the past few months, we raised over $100M to begin our important Phase 2 study of ALG-000184 in chronic hepatitis B virus infection and we are on track to begin dosing by mid-2025 following recent positive correspondence with the FDA. Our data presentation at the APASL meeting showcased the extension of dosing to 96 weeks. These data continue to support our belief that ALG-000184 has the potential to be first line standard of care treatment for chronic suppression of HBV infection as well as the drug of choice to combine with other agents aimed at functional cure. Additionally, recent data presented at the APASL meeting for ALG-055009, our THR-β agonist for the treatment of MASH, further demonstrated best-in-class potential. We are continuing our partnering discussions for ALG-055009 with several multinational pharmaceutical companies that have strong interests in MASH and other metabolic diseases.”  Recent Business Progress Pipeline Updates ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection 96-week dosing recently completed in the Phase 1 study and data readouts are planned for scientific conferences this yearInterim data from up to 96 weeks following an oral daily dose of 300 mg ALG-000184 in both HBeAg+ and HBeAg- subjects with chronic HBV infection were presented at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025 ALG-000184 administered for up to 96 weeks was well tolerated, exhibited a favorable PK profile, and demonstrated potentially best-in-class antiviral activityData from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (

Related News